NCT04022382View on ClinicalTrials.gov

A Study to Evaluate the Safety and Effectiveness Assessments of Restylane-Defyne for Punctual Occlusion

NACompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 18, 2019

Primary Completion Date

August 26, 2019

Study Completion Date

August 26, 2019

Conditions
Dry Eye
Interventions
DEVICE

Restylane Defyne

Restylane is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL.

Trial Locations (1)

40206

The Eye Care Institute, Louisville

All Listed Sponsors
lead

John C Meyer, MD

OTHER

NCT04022382 - A Study to Evaluate the Safety and Effectiveness Assessments of Restylane-Defyne for Punctual Occlusion | Biotech Hunter | Biotech Hunter